ArticlePharmacoEconomics2021

Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).

Marwân-Al-Qays Bousmah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.